e-therapeutics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

e-therapeutics hat ein Gesamteigenkapital von £27.5M und eine Gesamtverschuldung von £0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen £28.8M bzw. £1.3M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

UK£0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	UK£24.85m
Eigenkapital	UK£27.53m
Gesamtverbindlichkeiten	UK£1.28m
Gesamtvermögen	UK£28.81m

Jüngste Berichte zur Finanzlage

Recent updates

e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans

Jan 05

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

Sep 13

e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans

Mar 27

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

Jul 07

We're Not Worried About e-therapeutics' (LON:ETX) Cash Burn

Oct 28

Have Insiders Been Buying e-therapeutics plc (LON:ETX) Shares?

Mar 21

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

Feb 14

Could The e-therapeutics plc (LON:ETX) Ownership Structure Tell Us Something Useful?

Jan 10

Are Insiders Buying e-therapeutics plc (LON:ETX) Stock?

Dec 06

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: ETXDie kurzfristigen Aktiva des Unternehmens (£28.3M) übersteigen seine kurzfristigen Passiva (£1.3M).

Langfristige Verbindlichkeiten: ETX hat keine langfristigen Verbindlichkeiten.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: ETX ist schuldenfrei.

Schulden abbauen: ETX hat in den letzten 5 Jahren keine Schulden gemacht.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: Unzureichende Daten, um festzustellen, ob ETX auf der Grundlage seines derzeitigen freier Cashflows über genügend Liquidität verfügt.

Vorhersage Cash Runway: Unzureichende Daten, um festzustellen, ob ETX über genügend Cash Runway verfügt, wenn sein freier Cashflow auf der Grundlage historischer Raten weiter wächst oder schrumpft.

e-therapeutics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

e-therapeutics plc Considers Switching Its Listing to New York

e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans

e-therapeutics Ordinary Shares to Cease to Trade on the OTCQX Best Market in the United States

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

Recent updates

e-therapeutics plc Considers Switching Its Listing to New York

e-therapeutics plc, Annual General Meeting, Apr 29, 2024

New minor risk - Market cap size

e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans

e-therapeutics Ordinary Shares to Cease to Trade on the OTCQX Best Market in the United States

New minor risk - Share price stability

e-therapeutics plc to Report First Half, 2024 Results on Oct 26, 2023

E-Therapeutics plc Announces Senior Management Update

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

e-therapeutics plc, Annual General Meeting, Jul 18, 2023

Full year 2023 earnings released: UK£0.015 loss per share (vs UK£0.017 loss in FY 2022)

e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans

Less than half of directors are independent

First half 2023 earnings released: UK£0.007 loss per share (vs UK£0.005 loss in 1H 2022)

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

e-therapeutics plc, Annual General Meeting, Jul 19, 2022

Full year 2022 earnings released: UK£0.016 loss per share (vs UK£0.01 loss in FY 2021)

Less than half of directors are independent

First half 2022 earnings released: UK£0.005 loss per share (vs UK£0.006 loss in 1H 2021)

CEO & Director recently bought UK£100k worth of stock

We're Not Worried About e-therapeutics' (LON:ETX) Cash Burn

Full year 2021 earnings released: UK£0.01 loss per share (vs UK£0.009 loss in FY 2020)

e-therapeutics plc has completed a Follow-on Equity Offering in the amount of £22.5 million.

Have Insiders Been Buying e-therapeutics plc (LON:ETX) Shares?

e-Therapeutics plc Announces Board Changes

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

New 90-day high: UK£0.22

e-Therapeutics plc Announces Addition of its RNAi Platform as a Therapeutic Drug Modality

Could The e-therapeutics plc (LON:ETX) Ownership Structure Tell Us Something Useful?

New 90-day high: UK£0.21

e-therapeutics plc Announces Results of Experimental Testing on the Compounds for the Treatment of Covid-19 Identified Using Its Proprietary Network-Driven Drug Discovery (Ndd) Platform

Are Insiders Buying e-therapeutics plc (LON:ETX) Stock?

First half earnings released

e-therapeutics plc Announces Appointment of Ali Mortazavi as CEO

e-therapeutics plc to Report First Half, 2020 Results on Oct 12, 2020

e-therapeutics plc Announces Executive Changes

e-therapeutics plc has completed a Follow-on Equity Offering in the amount of £0.75 million.

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen